DeepMed Research

Jiangsu Simcere Pharmaceutical Co,. Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Phase 3 Study of Abatacept in Chinese Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate

Phase 3

Conditions: Rheumatoid Arthritis (RA)

Interventions: Drug: Subcutaneous(SC) Abatacept
Other: Placebo
Drug: Methotrexate

First Posted Date: 2016-03-30

Last Posted Date: 2016-09-13

Lead Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.

Target Recruit Count: 360

Registration Number: NCT02722694

Locations: 🇨🇳
Peking union medical college hospital, Beijing, Beijing, China

Study of Endostar Subcutaneous Injection in NSCLC

Phase 1

Conditions: NSCLC

Interventions: Drug: Endostar
Drug: Chemotherapy

First Posted Date: 2016-01-11

Last Posted Date: 2016-01-11

Lead Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.

Target Recruit Count: 8

Registration Number: NCT02652234

Locations: 🇨🇳
Jiangsu Province Cancer Hospital, Nanjing, Jiangsu, China

Study of Metatinib Tromethamine Tablet

Phase 1

Conditions: Advanced or Metastatic CRC
Advanced or Metastatic Liver Cancer
Advanced or Metastatic Non Squamous NSCLC
Advanced or Metastatic Gastric Cancer

Interventions: Drug: Metatinib Tromethamine

First Posted Date: 2016-01-08

Last Posted Date: 2017-01-23

Lead Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.

Target Recruit Count: 24

Registration Number: NCT02650375

Locations: 🇨🇳
The First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China
🇨🇳
The First Bethune Hospital of Jilin University, Changchun, Jilin, China
🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China

A Phase Ib Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection Plus FOLFIRI in Chinese Patients With Metastatic Colorectal Cancer

Phase 1

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Sevacizumab
Drug: Irinotecan
Drug: 5-FU
Drug: Leucovorin

First Posted Date: 2015-05-25

Last Posted Date: 2016-04-20

Lead Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.

Target Recruit Count: 36

Registration Number: NCT02453464

Locations: 🇨🇳
The First Bethune Hospital of Jilin University, Changchun, Jilin, China
🇨🇳
The First Hospital of Zhejiang Province, Hangzhou, Zhejiang, China
🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke

Phase 3

Completed

Conditions: Acute Ischemic Stroke

Interventions: Drug: Compound Edaravone Injection
Drug: Edaravone Injection

First Posted Date: 2015-04-30

Last Posted Date: 2017-01-16

Lead Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.

Target Recruit Count: 1200

Registration Number: NCT02430350

Locations: 🇨🇳
China-Japan Friendship Hospital, Beijing, Beijing, China
🇨🇳
Beijing Tian Tan Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳
The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China

and more 45 locations

The Comparative Study on Rh-Endostatin (Endostar®) Continuous Intravenous Infusion and Routine i.v in Combination With GP Regimens for Phase III B/IV Squamous Cell Lung Cancer and Biological Markers Exploration.

Phase 3

Conditions: Lung Cancer

Interventions: Drug: Endostar routine intravenous infusion
Drug: Endostar continuous intravenous infusion
Drug: Gemcitabine
Drug: Cisplatin

First Posted Date: 2014-11-05

Last Posted Date: 2014-11-06

Lead Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.

Target Recruit Count: 200

Registration Number: NCT02283476

Locations: 🇨🇳
Tianjin Cancer Hospital, TianJin, China

Study of Iguratimod Plus Methotrexate Compared to Leflunomid Plus Methotrexate in Patients With Rheumatoid Arthritis

Phase 4

Conditions: Rheumatoid Arthritis

Interventions: Drug: Iguratimod
Drug: Leflunomide
Drug: Methotrexate

First Posted Date: 2014-10-27

Last Posted Date: 2014-10-27

Lead Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.

Target Recruit Count: 240

Registration Number: NCT02275299

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

Fluorouracil Implants Used for Intraperitoneal Chemotherapy During Operation for Treatment of Phase III Gastric Cancer.

Phase 2

Conditions: DSF

Interventions: Drug: Fluorouracil Implants
Drug: Xelox regimes

First Posted Date: 2014-10-21

Last Posted Date: 2014-10-21

Lead Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.

Target Recruit Count: 120

Registration Number: NCT02269904

Locations: 🇨🇳
Heilongjiang Cancer Hospital, Harebin, Heilongjiang, China

Nedaplatin (Jiebaishu®) Combined With Docetaxel for Advanced Lung Squamous Cell Carcinoma

Phase 4

Completed

Conditions: Squamous Cell Carcinoma

Interventions: Drug: Nedaplatin
Drug: Cisplatin
Drug: Docetaxel

First Posted Date: 2014-03-17

Last Posted Date: 2017-03-03

Lead Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.

Target Recruit Count: 290

Registration Number: NCT02088515

Locations: 🇨🇳
Hunan Xiangya Hospital, Changsha, Hunan, China
🇨🇳
Nanjing Military General Hospital, Nanjing, Jiangsu, China
🇨🇳
Shanghai Chest hospital, Shanghai, Shanghai, China

and more 1 locations

Phase I Clinical Study of Metatinib Tromethamine Tablet

Phase 1

Completed

Conditions: Advanced or Metastatic Solid Tumors

Interventions: Drug: Metatinib Tromethamine

First Posted Date: 2013-12-09

Last Posted Date: 2015-12-29

Lead Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.

Target Recruit Count: 18

Registration Number: NCT02004548

Locations: 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy